Moderna (MRNA) 7 May 212021 Q1 Earnings call transcript

Good morning. May name is Dee Tamar, and I will be your operator today. Welcome to Moderna's First Quarter Earnings Conference Call. At this time, all participants are in listen-only-mode.

Following the formal remarks, we will open the call up for your questions. the being that advised, be call recorded. is Please to call Relations over this Moderna. time, Lavina the like I’d Investor At to turn Talukdar, at Head, Please proceed.

Thank quarter XXXX you results and everyone. today's Good to financial you, update. us call first joining on Thank Moderna's discuss business Dee Tamar. for morning,

our Meline, Le issued are the David our Officer; and to well the Hoge, Chief Chief section Officer; morning of as Stéphane reviewing the can Technical Financial access Executive this our Chief Stephen Chief Officer our Chief our be going and Zaks, Medical You Commercial slides Operations Juan our President; On by Goff, Tal call today's website. Andres, Bancel, Officer, press release as Officer. Corinne that we'll Investors our

filings vaccine, now the this cause and information COVID-XX has authorized a no XXXX. to will Private or the for materially use expressed note two turn see future been our Stéphane. over for forward-looking Harbor the of our which Before include these indication countries and world. call to made the on factors On see important other or update of many States information undertake please of to the provisions around I the implied the safety actual United for emergency the forward-looking slide this pursuant of from we call developments. in obligation will Act as Please and our new or provided revise result begin, that conference results Reform or call information differ to three, please those in accompanying results Safe risk important slide We Litigation performance statements. that Securities presentation and SEC statements could

COVID-XX for billion humbling to and engineers, members, fortunate walk business update. to Good produce for around Lavina. the made afternoon, is Corinne of Company Thank We sales. commercial the morning customer possible David start walks financials. you Company’s then details XXXX quarter its safe, taking emerged update, history doctors and through million provide well very made authorized mRNA two mRNA-XXXX, by to and call. about come B.X.XXX and in product virus We $X.X We’ll on to and X period now billion The has COVID-XX for around for believe am made the a Stephen mRNA-XXXX.XXX, are data for billion of I achieved, marks regulator time this currently of the the vaccine X million first again. invented our to first I never candidates, world. The never now the X was you, what authorized QX never I lead especially gotten for years COVID-XX ready XXX the has booster have the XX of proud doses protecting clinical night, income we tens in in This vaccine that you the months been Moderna of run quarter the single and this key QX of Africa. XXXX, been still XXXX, in Friday through conference close. quarter or of delivery to over now our WHO a we it people received human chase by had aiming Phase last will is am dose. by advance technology scientists, of XXXX to South losses. to us Moderna will increased $X.X few their $X.X will the first in for even a profitable the I I doses. review am doses and that team The everyone, join once the This quick vaccines, then to were a incredible fellow Thank have purchase Moderna you horse. world new will worked before should in good you our XXX available clinical relentlessly in minutes. XX vaccine agreement back variant-specific booster billion. with David be team adopted to doses give And vaccine, not the available where up million, am most Moderna million XX GAAP the XXXX. and who years operating $XX.X last Moderna or forecast XXXX, and world. doses able we be will be in $X.X ago alone authorization for XXX the countries have tolerated of The will our million go the shipped vaccinated signed We of also people been their had the the end quarter, XX supply and first XXXX, XXXX in well impact the beings team which increased product after total protect net supply our significantly. study, when fully investments very moment. late for In sacrifices have importantly, cash achieved in many year. At thankful cash not which many billion. even thankful millions QX countries human number more billion. revenues of very in

against showed to to XX%, identified tolerated safety We interim an date. to vaccine TeenCOVE generally update report of concerns X/X was COVID-XX and TeenCOVE analysis study, morning are no happy of serious with of well our Phase initial interim the mRNA-XXXX efficacy this our study mRNA-XXXX

BLAs this with start the filing of COVID-XX mRNA-XXXX. to FDA rolling track our on month still We’re for vaccine

is we therapeutics patient first candidate a have a COVID, mRNA our the liver the Our an type mRNA-XXXX. of genetic that acidemia, [ph] against dosing we propionic added genetic of for deficiency a another in first disease, Company. with candidate And rare as

where results highlighted QX The things about consequence we’re both most the of going. One the we decisions and year of work that I excited last is am made.

by as investments to is where our Moderna. to level So, very our to across invest scale sheet get the Using of excited the I balance strong board. look increased I Moderna going,

numbers in color. R&D some of higher than of In the last year. times R&D QX investments times were XXXX, X% QX XX%, X investments our higher. two approximately Just X Not or

the Moderna the functions of enterprise us do to commercial, now all you get-go. from For to like But as more operations, and a who opportunity we early build have for digitally pharmacovigilance, years, the many digital known been new has have trial much since clinical built days.

years, digital in at and automation So intensively looking we’re to the next AI. XX investing five

XXXX our in invest announced in billion to than X year supply more up to to times for we to is increase last fiscal that X plan doses. decided to invest XXXX Our week have digital We XXXX.

science at Let to let’s the me you we to scale? talk SARS-CoV-X share with why about invest that our to First, virus. decided Board of recommend

continue hemisphere variants of we of next its see emerge the New and the fall concern six that at the and around world, concern winter, to southern and months believe we over could emerge. variants

virus believe needed a shots we away. We will now be as while expect we believe not is going the that that booster for

over booster multi-variant-specific from standpoint, believe, booster. the also will efficacy a highest provided be time scientific We that by

ago. we versus a quite changed lot months has market the six knew what Second,

companies in the profile, First, to having clinic we good still variants speed generation mRNA a best-in-class variant-specific with clinic. first chase with Many the the as scale boosters. vaccines are vaccines, to manufacturing in are their have vaccine, emerged in high tolerability while the and efficacy, clinic

were There answer vaccine the XXXX thought pandemic. from East, the in to world the believe the market we’re vaccine for XXXX. for primary importantly, in shift six More and is in for has in the market, the COVID-XX market West when with perceived an the around nine what adeno ago for as governors and big or to or mRNA and supply be us the become We we mRNA us boosters more clear the protein vaccine. more South, series loud XX in a to and it supply are future the with North or months and versus talking vaccine mRNA hearing vaccines

strong believe will combined studies vaccine discussed to for to Vaccine from clinical more with goal the data COVID our for in Plus vaccine seasonal market is dose have vaccine our and studies our bring to the market clinical come. next single for Third therapeutics products clinical will we in boosters RSV pipeline. we development and We the for area at to variant programs CMV vaccine. in We’ll the through booster more move flu on is product. add to Day in the COVID-XX we preclinical two programs a seven in that months as have and years, years several three demand

to serve the capacity X the build So billion of to and doses supply XXXX deliver to we up in to South. North decided both

of and US. drug in XX% our supply substance the doubling drug in substance Europe We’re by supply increasing

and the are, We existing as come. more of US to partners, but Europe speak, ones in also adding adding we new at course, filling capacity our

four piece mRNA booster and mRNA have we’re cartons doses. hearing Small a in the we vaccine believe continue market. in of the Another in up not decentralized and the and shipment market XX refrigerated We best to of The XXXX and is today, weeks be in Moderna Storage dilution. believe and that, and minus even doctor’s mRNA wanted regular minus XX market to storage, our freezer is products a more that months Celsius the important and from this authorized on-site authorized to mRNA XXXX of improve best-in-class more feedback has vaccine, at Celsius. feature an office. of standard vaccine that only best-in-class does temperatures. not the to have will XXXX require six XXX we in the We we as product, pharmacies move future

are our oncology, called this in for is pipeline, milestone first with the have, Not we This in study dosing patient the but vaccine clinical disease. infectious We disease. is of Phase in and now clinical yet have I the the only announce cardiology rare we genetic propionic morning candidate Moderna. study X/X in most another disease delighted therapeutics also start our in Paramount. acidemia studies innovative believe, in to do The of

my me recently network. continue on our this have build familiar Let X,XXX commercial close employees. Japan We’ve now We remark to Moderna and KK, slide. we incorporated

invest to in to broad a going Asia-Pacific mRNA our And to sheet we towards as allow strong scale the Moderna can. accelerate and continue many push XXXX. and given billion, of of as impact $X.X to we’re platform balance people maximize to will We

processes, for the Let the vaccines. on perspective by protection will vaccines the pandemic. of capacity that is have XXXX, no in art no in talented in manufacturing any in mRNA who individuals high-quality the mRNA purity GMP-grade skilled announcement no world. processes States more companies of and faster share There would yesterday of billions world, most supply developed that industry Ambassador, our will quickly which processes, time mRNA a mRNA property There who purification allow to XXXX support Trade are help We COVID-XX them critical not me government file analytical manufacturing and high the hundreds approved of to And afternoon are the [ph] by vaccines. intellectual or making or waiving There United if this then supply is believe regulators provide world around the is millions the idle of vaccine. clinical US run

pandemic, in patents. Company’s the Moderna X, October the XXXX during have announced COVID-XX-related will enforce statement not that We issued

maximize get protect that the we the beyond; XXXX clinical We very we adapt to to and the which third, vaccine supply pandemic for results authorized what to we’re second, variant-specific build vaccines that to the we announced and find statement to a can have You to to announced end booster, doing: best capacity, people website. highest in as can; encouraging X mRNA of doses week to XXXX which additional many currently up way efficacy as with vaccine last have is XXXX, yesterday. believe to our billion continue first, on for

commercial to Let you to Corinne? update. me now turn give Corrine the

Thank good you, afternoon, Stephane, and good or everyone. morning

Company commercial authorized COVID-XX on product, already first have the quickly. into back we know, Moderna’s and of As all is vaccine our very of turned it, a you

to first global our am I start delivery and second quarter. which announce of vaccine happy low- will you access In and middle-income with total, our millions agreements, supply is to progress on those XXX with So of our our for XXXX in I agreement XXXX first the beginning COVAX in and and people for provide to in countries, occurred with COVAX, the quarter is to give commercial principles. signed the that this in at today, year. period. agreement the million an keeping in I’m access quarter particularly delighted doses our the update most will the recently

in COVAX of XXXX, doses additional fourth Moderna have an in delivery of million XXXX. XXX option Specifically, will in quarter for million doses an will XXXX. the begin XX

the commercial collaborative We important the making Health agreement of are World to teams and grateful all UNICEF, this in a Organization, Gavi, efforts CEPI, supply reality. the Moderna

now the supply agreements to XXXX. signed additional and Moving both XXXX for

agreements supply with in for additional an doses in XXXX, options additional XX.X and signed million doses XXXX have million and Switzerland and Israel with option X.X We million X for for XXXX XXXX. with of XXXX XXXX and in late for doses additional X an million

view countries, Asia, for We countries XXXX in and same beyond. are as time, And XXXX in continue other said, in the and purchase delivery million our the addition, vaccines to with advanced and Zuellig provides already also in agreements signed In we an we technology for have totaling we from new adapt on in reliable Taiwan. Pharma, Southeast Botswana, both Stephane scalability efficacy have Kong, In slide. is the discussions, this consistently distribution and those to speed partner variants, supply doses discussions delivered be with of signed mRNA at to with no contracted to also here have have listed allowing their new we while XXX deals XXXX we of governments necessary the there Brunei, total, our that to agreement high that are and hearing countries announced with Macau manufacturing. that Hong

governments in pandemic we other We to ahead variants. the supplying helping signed agreements for countries various us the vaccine placed end trust grateful getting forward and the to with have from look we the are and of and

now me Let turn product to sales.

for doses of delivered XXX of doses Israel we first quarter. days approximately expect and the $X.XX within $X.X the sales million the the have US, the the the million this of for Our approximately first the the end we in government to XXX sales the authorization, of emergency of doses. the outside EU, and million million the in US use to the complete delivery government of were sales recorded Singapore year product were of million the second first to the In before quarter. were delivery completed were our successfully doses to billion United Switzerland, XXX the States delivery XX quarter US and — US first and second XXX Product for billion Canada, $XXX

the of to rollout reiterate quarter. are we produce the we US production earlier will know, you first quarter similar production I we I it’s vaccines close, To second the to to into US ramp, proud call be now and the the one to roughly that to market, quarter turn Meline. to started of as global in continue and and part in solution. humbled want As ramp that ahead expect the ramp be as over such, in ex-US the XXXX the of David

on presenting cases, last our also with some as Today, we underlying the on earnings with In drivers to trends. analysis we are Corinne. providing performance additional our of you, US primarily going quarter provide an GAAP detail clarity of first results, call, an Thank basis. background, results actual forward. view greater Okay. key this of provide we XXXX along updated With are financial

million in quarter was $X.X QX $X XXXX, to year. compared to Turning revenue last total billion first in of XX, the Slide of

the on discuss $XX COVID-XX to December in candidates. revenue we inventory increase. year. growth for billion Selling, the I million our benefiting previously the personnel of announced variant-specific in period later to were expense first in from our development compared as product well revenue COVID-XX XXXX, increases, by the $XXX also prior in vaccine to for of BARDA pharmacovigilance quarter, expenses in $XXX in vaccine primarily of Headcount vaccine. quarter development vaccine Grant multi-valent Following increases outside driven $XXX booster, was related million million from and XXXX. to Research in general increased The to activities, driven $XX sales contributed were the spend to $XXX in which to of and detail efforts of increases first-ever same costs costs, administrative of more compared XXXX, million million QX, collaboration sales sales our our for million activities commercialization increased pre-commercial will substantially our the COVID-XX in clinical COVID-XX million spending expenses and expensed grant development higher XXXX, QX in vaccine QX for by year-on-year $X.X around services and Cost first accelerate product period slide. and $XXX with were vaccine due recorded for a The as our COVID-XX was associated same including XXXX. globally.

year. and income items. and slides. in for a last when diluted the also a taxes we provision net utilization well compared the effect further per from diluted outstanding $XX as the for Our share operating $X.XX. our I net loss billion to reported of QX recorded count million loss of of includes reflecting on following context of was RSUs provide on in We profitable. of year, carry-forward, of a in we a QX income diluted our Please basis were note a benefit same. XXXX, basis as be net was Previously of the on Earnings to million same $X.X shares began loss this number share period discrete net as will $XXX options that basic were position, now

COVID-XX billion end $X.XX additional of of customer reversal of commercial selected ended is information two $X.X our year. last sales XX. by was $X.X entry commercial The results operating provided for compared that QX net me with US to last year, driven an vaccine. We We first the financial XXXX, and inflow areas outside rest of increase from to $XXX billion, deposits are providing and operating XXXX. in financial investments billion driven expected The XXXX the on our by cash Slide on in QX few cash cash from activities cash let activities quarter to flow QX QX important cash quarter. to this Turning market for remainder for operating Slide XXXX to cash a in used Starting of one to compared the Similar at in received future Net the US year QX updated of keep our in our cash build purchases outflow by of million framework before for net when quarter, mind entire the summarize with was last started world product supply modeling to and sales of chains, in performance. XX. one distinct markets. and the

sales US scale mix quarter in is ex-US the in one supply roughly chain, Our in chain up in of the QX. geographic advance was which our supply reflected

QX, move we full As supply forward toward the ramping also capability. in chain up is ex-US

the a includes $XXX Turning have XX% costs favorable valued material royalty yields at If to costs, expenses $XXX recorded be costs the further inventory in benefited of somewhat incurred. that period vaccine, of hence, cost would of XXXX, during this sales cost balance XXXX of in future US not expectation well goods of vaccine of vaccine. XX, expensed pre-launch sales costs million We remaining costs cost, and development Prior our expected, of production authorization and our cost following in as vaccine year what facilities. recoverable our and inventory in of or started in to actual the first December million, Slide third-party QX entire and would been we will balance were these of or began the quarters authorization, the COVID-XX was cost inventory the as to zero-cost and sold costs. in emergency research by million inventory $XXX our of sales, sold our driven impact inventory. the with Almost as commercialization million use $XXX through warehousing our upon manufactured, XXXX COVID-XX our capitalizing was product way. of favorable quarter sales We of logistics based the COVID-XX inventory

cash to The reported billion from turning as XX. Now, The $X.X and as position our by December and of driven on XX, cash $X.X was billion, increase XXXX. Slide balance up was investment XX the at in customer of supply cash of The primarily investment billion to end net $X.X $X.X XXXX. deposits end product at COVID-XX increase of billion balance increased future the of December deposits for of customer from the QX vaccine. XXXX net March

The the at of Lastly, to development let with comment tax-related in platform XX. the activities of investments XXXX. last items the $X.X Slide carry-forwards decade net develop on have mRNA research, operating and in me our balance over billion end resulted startup on significant a loss

maintained course will assessment able of assets. on against its financial cadence related XX, tax realize December the these of to weight we of As rate the Company XX, reporting available quarterly information P&L strong XXXX of allowance outlook. our on available included, XXXX, flow concluded a the that as effective but likely the majority the based in be activity. than of earnings. the net also will negative, analysis substantial tax it We valuation carry-forwards. results, the our full assets based of loss not valuation both deferred not allowance our only period quarter is each a evidence, of first pro-rated perform allowance during This and more we expected majority April valuation deferred latest that over pretax our considering March After tax positive The through to the our and

two quarter our discrete which tax rate. tax provision first in benefits in QX, our recorded lowered also We

in utilize related assets, years. benefit the we deferred expect valuation The portion allowance first for release tax of future which the to to

benefits to tax stock-based with The second compensation. the excess associated related

we sales, and in full-year the as reflect million end in up updated Based for to Slide million Signed financial our on have plan expected lower product total from our recognized network, current XXXX to the $XX.X progress available advance dose delivery global the framework been XXX of of capacity for delivered agreements supply in raised the XXX level. doses QX. have now XXXX XX. on ramp anticipated manufacturing XXXX revenue continuous Turning purchase doses at microgram including XXX to in billion that

Our expect team million Further, of XXXX doses a of for XXXX. to continue are working range up million partners XXX our still we deliveries XXX doses. manufacturing QX to and supply X to billion to in

cost Our sales of the and and total includes of warehousing, cost logistics royalties. manufacturing, third-party

XXXX, some to going cost total as for product model be percent approximately variation we with sales largely driven the For continue of quarter-by-quarter, full-year average a sales XX% of to by price forward. average selling

let expenses. the global tax previous low-teens. current compensation. US This is any include effect discrete mix of tax visibility year. stock-based be This accumulated QX, not expense on basis. expenses XXXX a the Now, comment rate billion utilization better me $X.X expenses planned based compared policy and stable benefits actual QX, forecast, now to a QX were internal does primarily our the Based increase now approximately QX the related the benefits lower our and of we notable in mid-teen mentioned R&D and QX on expect compares the SG&A sales were development our future underlying related for carry-forward, like-for-like potential this the clinical We in In the by to expense in timing a commercial and activities quarter-over-quarter run of basis on XXXX than in costs. trend expected of in driven all-in of net rate starting on on remainder forecast range. to and our to forecast loss operating expect discrete

this We as our evolves view will business further. update

regarding Finally, capital investments.

XXXX the capital And announced on million $XXX for forecast over investment remarks my financial expansion call our from now $XXX raising XX. the million investments for April performance. to previous are planned capacity concludes as range to I concerning our This $XXX to million turn to $XXX We million, including of Stephen.

into before David. the COVID-XX reminder of study you, our of that of I’ll against discuss of is a go mRNA-XXXX; booster rest single a evaluating X vaccinations variants and our of our begin data mix XX and initial strategy data, booster with available booster before three I XX mRNA-XXXX.XXX I which ending concern single Phase pipeline. and the multi-valent summary with booster moment; of different our And from Thank of mRNA-XXXX.XXX, mRNA of a overview will dose combines with micrograms a strategy a vaccine. the vaccines: an and data mRNA-XXXX have in a which just both XX-XX today candidate, vaccine vaccine micrograms in

dose addition, a the booster XX available. we’re Data microgram also the mRNA-XXXX.XXX. XX In and booster from be XXX of lower evaluating shared microgram of multi-valent when will

events X Now, the backdrop, generally data. dose Starting booster in received reported approximately previously move XXXX.XXX. X let’s X events after participants participants the fatigue, commonly adverse There Grade were or with the and frequency X and in XX% and systemic XXXX.XXX were to our observed XXXX no or local majority either XXXX who Grade days safety, who events of the systemic and commonly were reported. pain reported most Phase comparable that XX% solicited of Phase approximately The seven those within study a arthralgia. most after dose and received in were second and of study. XXXX site to COVE our events injection with The with the reported severity of moderate events mild were myalgia occurred headache, events local in

variant, a the On SARS-CoV-X that in as the these New again, against a show P.X, vaccine one variant against the week drop were in was figures the And in after and identified of the serum the decrease Recall, of titer of from three-fold difference levels next reminder, two the samples figure first titers a The first described vaccination after second dose one left-hand Republic and neutralization mRNA-XXXX. side serum slide, with in primary there B.X.XXX from our the variant in Medicine neutralization were mRNA-XXXX. of South the in primary series Journal in of And Africa. pseudoviruses on samples titers six-fold series England week papers. published of Brazil. neutralizing

these to peak essentially, So are close titers levels.

a posted side before manuscript individuals from the reminder show to yesterday of concern X X from against were to series initial our time participants At against the titers participants point, this results prior booster high our studies figure titer Phase wild-type remained previously study. of But slide with study detectable primary this mRNA-XXXX eight these variants our X SARS-CoV-X vaccinated enrolling of is a study in P.X, our the that immediately months were levels booster of lower. of six in right-hand figure vaccinations. A either neutralization X titers. pre-print The the much booster the all or having with titers Phase roughly the and in B.X.XXX to almost On Phase bioRxiv. Phase their

of approximately had fact, below at the assays participants limit this of time point. quantification half titers In

So, titers time waning to neutralizing is concern with activity. more is rapid both of variants lower lead that of titers clear it apparent of against that loss and

Turning either B.X.XXX shows levels of to increased The concern. weeks the two P.X or wild-type that after slide. booster virus, and next mRNA-XXXX data as the against XXXX.XXX, titer well of both the vaccines as neutralizing variants

peak boosting mRNA-XXXX. effective of variant. GMT the neutralizing B.X.XXX more with In titers XXX achieved against the similar and with relative GMTs the higher the Vaccination fact, was ancestral variants of wild-type X,XXX to after reported than compares This looking booster the with vaccination. boosting strain the increased XXX mean of specifically we against primary or different in with levels viruses levels to strains, narrowing mRNA-XXXX.XXX tested When previously against titers vaccination the mRNA-XXXX. when following boost, geometric between three to following mRNA-XXXX.XXX at titers against at gap

lower arms, by excited mRNA-XXXX.XXX. see initial and arm time of over as dose from multi-valent data and we’re data to well additional this encouraged data we’re the as the from these arm a Now,

to manuscript. next comparison last from the On highlight like I the slide, one would

from of Phase the series strain sample a titers there X primary a assay approximately vaccination with achieved X,XXX. mRNA-XXXX. is are this study following neutralizing left-hand participants the against and ancestral [ph] On GMTs are in

On the is of right-hand just spoke the side data through. reproduction a we

variant able top micrograms Looking the study. of That to the titers and against with specifically increase to was level to highlighting XX, and I’m a titers, development updates get of We’ll I’ll in dose booster entering time variant titers data, I concern A watch mRNA-XXXX, to slide XXXX.XXX, was vaccine booster compares in B.X.XXX of a the ago, of of a closely XXX against titers this as candidates bar to concern. that and micrograms the points. study. continue of or our forward at highlight snapshot as moment few. this XX as dose of in look XX a a are the this is clinic, mentioned high neutralizing neutralizing able which On the X,XXX of subsequent

in is on Our a track CMV XXXX. Phase X pivotal start vaccine study to

a study also XXXX. Zika to vaccine X Our expected Phase is begin in

from X toddlers. And This Phase respiratory last combo we cohorts Our is X hMPV/PIVX RSV Vaccines are study of our still in at positive interim month, enrolling continues and that our currently adult Day Phase enrolling. announced pediatric data older vaccine vaccine, in mRNA-XXXX.

mRNA-XXXX XXXX. Finally, within X expect clinical Phase ongoing we study modalities. four we Outside our across a flu of vaccines, to concept vaccine trials begin program, seven in have proof of of

Our partnered is program VEGF Phase X. with AstraZeneca a in enrolling

program dose X ligand, Phase is study, enrolling in partnered are Merck Phase X also personalized trial. expansion X ongoing. second in X Phase also vaccine immuno-oncology, triplet Phase Within X Phase ongoing the intratumoral partnered partnered Merck OXXX program with Our with is IL-X a AstraZeneca is cancer study. KRAS, our And which our with and

mentioned, are XX, study can Stephane propionic have in pipeline. to academia. as Finally, our development On full dosing the we Paramount in started you slide pleased see

infectious portfolio over we I’ll our now vaccines, therapeutic In have seven us clinic. addition on. disease to to in turn take the the Stephane now programs call to of large

and Thank you, David. Corinne Stephen,

$XX.X have signed increased agreement now purchase been to billion. advanced XXXX Our

we capacity believe greater XXXX As doses billion than we could investing because need build supply be X to in XXXX. the in look XXXX, into we’re market of

additional First, week have for morning. but this Switzerland boosters, for and signing children, last series for also already prime variant-specific Israel XXXX for countries we APAs

were If game the APAs some you signed they are these countries again, recall, of the XXXX, XXXX. first who of XXXX countries and and for ahead in

anticipate COVAX XXXX. with million the supply to up to Monday, partnership announcement XXX Second, doses in we

Third, governments we with XXXX Moderna. that active having have are all discussions with the APAs signed

Moderna us series APAs prime Fourth, but believe from with why have more This the We again, fortunately. decided in supply mRNA that governments efficacy XXXX XXXX. APAs we current in supply cannot already are boosters. are of having do these that deliveries, XXXX supply also to XXXX vaccines to them for But wants XXXX store. into XXXX. asking deals governments we because enter discussions numerous for APAs new with many we high For than easy want in more are supply invest us from they to in discussions we because market current that is XXXX our can and not

increase to that against innovative our research innovative and As vaccine more pipeline industry, we humans. look impact to by the years, most we’re bringing the more clinic in vaccines next investing hurt have XX to at five the in viruses we the

oncology, three We should therapeutics and clinic now and rare the in in in autoimmune disease areas: soon disease we as are well. be clinic the in cardiology

in invest our innovate the example, with in Vertex. partner for lung We’re delivering like continuing for to science, mRNA and

As to more XX prepare Moderna scale we’re we impact, investing to times and continue aggressively. that’s

our accelerating spend around in and in a are investment million in we invested $XX million From We XXXX XXXX, AI. digital, automation in $XX of digital.

that, are XXXX. We planning triple in $XXX almost million to

across learning the of we ensure ensure to and investing can operations. We’re transform to the board to accelerate high-quality in R&D clinical pace

We’re high high-quality, for investing digital to ensure scalability manufacturing. in

and so We pipeline spend pharma expensive change promote highly big efficient commercial, sales effective commercialize of in force inefficient are building our large, and can the drugs. to want advertising We manner. we a need-to paradigm to that and

Company. pockets don’t is are creating that simple, functions, also want organization. the scale AI. do of We AI patients exciting is AI to Our doctors The most But for. so pipeline not corporate have our rhythm is first-in-class we launching yet academy. excited DNA. I’m in part are finance, our enable legal, companies excellence and and medicine without AI we large Today, an corporate across on to waiting that of some HR,

have to previous in evolution in workforce. but hire the everything their be computers have the skills how in personal It and AI our would years entered XX development, HR, ago in management business grow do. when in and is science, we we to everywhere. company. run at XX Moderna exposed for to and new as talent, their to manufacturing, So, as part in the same AI change understand DNA. been become in finance, they of We AI want want use team every clinical commercial, quality, few great part, We we AI

you And systems, other. to we As we get integrated have each of more digital know, connected more have data. many as system, we

we platform, the is more and biopharmaceutical I our learn the get culture building our faster. Moderna willing fourth to we creating scale believe data, infrastructure, industry. [ph] And keep mRNA strong team, unique As balance our and in we are cycle. digital sheet, Between our our

is software, scaling after of you opening manufacturing XXXX Norwood reopening. are but As or to July there the is Many Moderna, part way. in another you of also that a of of aware site visit came

feet. We building next square around added North. called it MTC Center South, XXX,XXX In XXX,XXX around called Our building a square feet South. XXXX, added Technology it to or Moderna it and MTC is and we

that investment We week start a to XXX,XXX pleased is now this building, after building. to new announce feet. East, some have MTC which and to later are another That year, employees will welcoming Moderna we this access the renovation [ph] square

we campus, that hold square in and MTC campus. around [ph] now the on entire can more XXX,XXX have the have add buildings So to now and feet. access We them building build now this we also we

responsibility. Company. be about to for not by are that we committed We Moderna a strong but has Company as medicines, positive a in world, a sense who of are deeply only want the also We building force a

workforce first clinical recently belong, & also Action Inclusion in for and Last we figures our year, published diversity And diversity. our We inclusion are to we expanded time. pledge. have commitment the Diversity We committed ongoing to signed reiterated increasing for very diversity trials. the CEO our

the environment. We are deeply to committed

renewable be net our site should our from target be on energy to with not zero carbon we as a We will to Cambridge is Company. energy source will sources, any Norwood working renewable have decided that and and when offset and we

We’re also in more. we the live education River positive to the to communities Charles the much from impact Cambridge encouraging and our and cleaning stem feeding a volunteer, which have employees on homeless in and

You on of can find online lot resources a website. our

to are innovative the of to and to we using am I close, As colleagues a collaborate make My how last want chance do. and get proud years I I medicines to Moderna has first to or the of biopharmaceutical medicine industry. platform thankful at to come I to convey team over to the what help us treat Everyday work stage. more this done people. the to make do XX information work have what we we protect

medicines as we years I Moderna, changed five, over we no relentlessly. Over beginning. future execute ever next transform the other of started the XX the we at to the This XX chance as medicine. virus, potentially SARS-CoV-X I continue last months since is But chasing QX, XX, in just a like has have and to look believe company

update. Operator, things later, team the holistic we’ll with on at has you Day to are Day questions, Annual Before clinical very new summer, the taking share on few X, Annual now. September with like weeks we Stephen any connect for a of will would your to I be that you you. be as cool Science our And question to end want May R&D remind in and his to event our going take some hosting happy to XX, this

from Your [Operator Thank ahead. Goldman response line with Instructions] Richter Sachs. is the Please you. go Salveen first of

I my here. for have questions. Thanks morning. Good couple taking a

what program of year? if walk whether COVID-XX dynamics to vaccine could — the we’ll kind could pipeline? just from them see discuss be move supports endemic program it’s and see what that address it’d the IP, with us that? And as for I XXXX of for you we else of vaccine WTO to mean through forward, And contract to regard to if kind you nice look mean, Moderna? great move Thank Secondly, PA understand from data So, you firstly, might market? ex-COVID the this that variants see an just towards the waiver third, in you. does US see if you

It’s morning. Stephane. good Salveen,

with first then Let Stephen. to I’ll PA question me question and your start the turn

doesn’t does IP, what for So, mean? on the it believe I change Moderna. it anything

manufacturing we will is This I As pandemic. no world. my a our last in not And in we said technology. there October enforce new patents had I’ve as said, is during mRNA the said capacity the that COVID-XX-related remarks,

And vaccines don’t the in machine, know trial, if go how or make run data, approved scale to get doesn’t all who mRNA to mRNA. whoever people manufacturing. to have Those have hire will processes the six go cannot XX process, buy even then analytical were You get product invent invest available, wants then and people XX things happen manufacturing those exist. These months. the processes, clinical they purification will the or to the and do

clinic as We to smaller get know, there have line. that you in trying the this a still been are to working companies finish And are years. for some at mRNA products the

we later, the you more a approval. know, just technology mRNA kind and speed of the being contracts, On over during moved the is, didn’t dynamic protein news and data didn’t I new market I contracts sleep before described news contract, clinical year the because then through get came pandemic of just so, first last data my changed, move, in saw and XXXX many since the as which as [ph] on want that’s contract. night. last it, especially the then is night countries, on they And to the lose came tremendously And the started the along, mRNA adenos to clinical case,

advising big — actually believe scale virus response around have because, and the really then fact, you then not is still again it. proteins in we less had. governments question And issues the you products adenos boost vector adenos, and that by with same will And the low adenos, give are authorized the — get questions companies scale-up have, efficacy the time anywhere somebody have adenos — from more had manufacturing West. that safety in adenos you which scientists the so to And that the over definition, less the the of

their believed going is long the given as clinician. as for and critical. talking be this to the this year you by do at are governments way and educated what last science, Trust will the They are think many variant-specific boosting governments, is me, time. boosting gone not So be going quickly. governments their And a believe doing, presentation, going to to well. as and stay virus going which is I to they clinical pandemic marketplace, what right is away. They have Stephen’s to be believed every They believe scientists the is showing the this believe look massively data we’re got to from saw you

but in as are And very can that prime on and we discussion or is because up that in we’re booster. which incredible and up notice the what can for we with XXXX.XXX the we And be know, same all contracts with based those unfortunate me have all year we her a governments are XXXX, do people, we the because, next that’s suffering lot technology and then before, we’ve sorry, with around because for XXXX-dot-something variant it’s an or can supply to the discussion we’re difficult both series news manufacturing have dynamic discussions same us to the you are we more the almost the data to contract they Corinne This most announced the supply governments, having have next more, say, beauty current of the this new agree those will is, world. the now already exciting the choose a get XXXX of variant. materials. no them the happening year, but active want change equipment XXXX competitive that specific same them. in for to before and X same you never to very on [ph] very XXXX. called clinical having with a with supply room, right short process the discussions to raw team XXXX.XXX them to is can called and same position of a and new with is, billion advantage and course, governments is or with have investments to great calling in we But couldn’t look, those that now And we in given so, of or The give about them more our

dynamics. you on So the for sense PA? that’s kind of give a Stephen,

Sure. Salveen, for thanks question. the

the study as Paramount dose program, at going know, as So, is of looking biomarkers part acidemia you propionic a be its to optimization. the for

one. we’re forward. going looking there. it’s we the that optimization consistent we’ll perhaps correct to very dose first no level at be the data the guarantee multiple levels. sure of a make indicators dose develop to — will and will at we’re are cogent is first a that seeing we there possible impact if bring But It cohort early And be that before set and is that be And so, looking that we and we dose going study

dependent possible So, see data that on many we things while our up year, would I this think control. it’s beyond it’s are that well

mentioned, general more portfolio, our enrolling also generally, you a is more a asked look could programs been if data at that’s Phase you X a about for we see VEGF, It’s and we broader program possible while. Now, as question from the that.

is continue cogent data open are producing and, forward. of of we will Our data similarly, many programs intratumoral again, PCV it label and we a highlighted, set, programs, to when and bring and enroll. we’ll complete course, KRAS programs, track them as then closely we that those ongoing they And have

Thank you.

Salveen. you, Thank

you. Thank

with response Please ahead. Harrison next from is go Morgan Stanley. Your Matthew

a me. might refrigerator you guess, you’ve an just think I I regulatory Obviously, with on Great. you neutralization efficacy that? on it’s the COVID some about questions. [ph] of great that just PPA has be of talk Do titer hurdles? might One, of given And from what a sort that then struggles now the vaccine you talk study. the a of view next-generation think you enrollment. spike? sort those into or about the second through you taking question, past, stable. follow-up the study gotten your one right, just gotten can gotten you’ve safety Stephen, a been actual morning. might in if you’ve you see you Can I is if around enough in, patient that that the full And to for study patient know for for to enrollment? where the not think do Good be path run it’s two it have vaccine, Thanks Can the think

you, Matthew, for Thank questions. Sure. both

mRNA-XXXX. stability candidate, believe, our shorter profile. first, is second-generation construct is have I you’re So, which that we refrigerant referencing vaccine longer think a much on, It could a

probably we’ve to we in bit that think But initial not too will But, conversations, may early upon wait see be previously, with XXXX the that it’s enrolling will — a on and some go that will announced a say we future in As dependent series could as to the like in X until into vaccination data have regulators. little path for study, with we that that premature Phase and probably we again, highlight full obviously, conversations ultimately, until a comment to that data in primary what study. It impact that’s we get of it’s the possible function regulators future. would and have the it booster. I look it’s regulatory started

the we’re over years past to pleased PA you participant, — to is and very patients hard team working in possible. hard patient that As we’ve the that And as enrollment, study. it as quickly additional relates first been the over as first to coming yes, quite the working the have mentioned, on enroll enrolled

of issues whether tell of and we’ve time previously think actually that here in any I addressed broken will the through we terms had enrollment.

that And be enrollment made that provide we’ve subsequent progress. expanding term so, hopefully, near that we’ll in on able updates to will the demonstrate

you. Thank

with go Your Ted is from ahead. next Sandler. Piper Please Tenthoff response

the Stephen, and Great. balances, detailed financial David. were? because including us is Do pick data six of shown, just Thank you’ve Thank maybe booster the that re-dose for the kind can or all where you re-vaccinate thank you. sooner the actually take you running strategy to the see of maybe through the can Congrats much, detailed timing? step what potential to as of very to what of I months updates, than like? on us sort so wanted look a eight maybe going on to the And tell levels and forward, success. need all booster up we you you

For boosters? when be getting we’ll

also don’t and question, will Ted. do is to the immunity to for highest at means waning raging we circulating not do countries well there saying, of on data the Look, that to think way when have that not broadest immunity. of of happen neutralizing start maintain vaccinated We, that to renewed the we and But is have want largest leading have breakthrough re-infections neutralizing Thank We point by ensure in expect Moderna, boost variants that pandemic to as concern. know that levels infections. know. we we against believe possible the the a outbreaks then we to best immunity some do I you maintain number

If does feel of you data neutralizing neutralizing the concern. time of have an certainly it XX-month that it least that have longer were in the at and the as we a reports, the by not, that’s earlier, Again, immunity six- previous vaccinated as whether data half or posted horizon, the participants — or a at you approximately look a ancestral if the some infection in variants as our of vaccination but against. detectable today, correlate I don’t series that seems immunity over against know weigh indication we that our immunity of strain data titers. look others well to at clinical against like immunity. presented we booster is to to neutralizing They waning studies, have no published that And primary measured they

the see against can those a increase protection, duration boosting will the boost annual virus. now, to to against think logical right also we’re the to for to but we an primary if least looks longer evolution immunity titers those of long as do while on to perhaps the a booster we our them both nine probably like see thing you that after give them is XX-month series way enough through vaccinate pandemic. So continuing of of variants those That at now, concern, their

see fight you variants generally of therefore, is not to is divergent and see will know, last may protect going do that that the as Right variants we be concern going best evolution continuing here, strategy, pandemic make to the the still when least at protection of our of be which are strain think path point multi-valent be number going to globally. a we’re that one this therefore, to XXX are against and unfortunately Company, ancestral the booster, and and think variants is in we believe And concern we we’re updates people can now, variants. our as it broadest vaccine, a data, And virus we the paths. we to follow Now, widest many to the add first way against to a of to Africa. necessary ensure as combination, we waiting many beginning, vaccine. provides of as the identified multi-valent a just many to that there we ensure of about vaccine was are this range immune to the more as South the XXXX, receive through broadest But think that committed,

you’re the work doing. guys, for Incredibly Thank you, helpful. all

Ted. you, Thank

Thank you.

ahead. Yee with Jefferies. Your Michael next is Please from go response

questions. some be form it the the to of In had it. going bivalent Stephen. color was follow-up sounds make I there? of just Appreciate Can is open a strategy, think offer actually Good strategy because that might if increase it the Can And best, the also maybe color just WTO. follow-ups. material the were other I like to some back the you you. you capacity, global question second I maybe Thank the about etc? you loss some like Hi. words, easy. variant don’t patents? One just can So shedding on that the of have just talk there supply raw on capacity offer morning. around about any even to view important question some light two ability

to what trigger beginning at Thank for just you. point that pull manufacture the that all So, up would ramp and on you XXXX?

Thanks, Michael. It’s Stephane.

Let me and start the on raw material IP. the

to to focusing is back again One if material with Going from will you said, know, Internet, on out start as somebody find cannot there. I figure by raw mRNA. was start first make supply. patent, on office how all not idle on which, no mean, there the what that one website. US to scratch, you will Patent And the mRNA large-scale player I have because that’s capacity to

you to XX methods to is figure need? need? methods How you companies what for things, need? are out vaccine and machine take the not And out figure years they to trust And that What there so, the [ph] been figured have trying once have will companies even have you or purification it market to that finish one get mRNA? analytical are carrying in you mRNA on And that time. still those easy, for me, do do all with you you how the to line. are make What out working are on clinic which, is going decades. XX It

believe at I to the really is on, Stephen, the mRNA already really variant? the for is that least that It issue. topic but comment is want so, the [ph] believe have not I protein, And you the IP is could think question. wrong take and this mostly driven. not issue. I might I adenos This had critically do technologies this impact other

Yeah.

So thank you, question. Michael, the again, for

as the data waiting still our as suggest And are So, mentioned, and we we with variant. highlighted mono-valent benefit is multi-valent published previously be to I by the the or we going additional have then we’ve that to as strategy, have, clinical to approach. data is therefore already we with shortly, that does that. we clinical mRNA-XXXX.XXX expect potentially point, — adding preclinical highlighted The this for that And antigens is — confirm does multi-valent winning dosed there on and the have that to are at people have a we presented benefit approach. data a

ongoing we to important is this battle. it’s view recognize think an that I

things. we down current think on mRNA-XXXX.XXX, going forward the because manufacturing? so, we’re do your question We’re bivalent of we we add about not because continue when path doing the And needing move and the to go pull trigger but vaccine, and think we’re already that multi-valent path with that of bivalent vaccines manufacturing, done to the

we happening virus support that’s already time maybe that establishing building think think and of a trivalent, process updates in we stop there to and going ahead. It going the so, And to not do platform suspect is multi-valent required, to standstill because to is in we And be going keep and the quadrivalent. to multiple capability, vaccine. be will evolving, the we are

of But completed still into we’re those scale performance be this needed. come able sufficient of in scale are to think to move batches and quickly all confirm at manufacturing distribution point, waiting We commercial clinic. GMP we at for that data have shortly to we to if

Yes.

mRNAs are where a strategy, lot the look nucleic it’s because mRNA easy the from few you time. add And because same not to Stephen have change so don’t analytical multi-valent those a is size. point it takes few standpoint, is, product pushed — people it GMP a multi-valent mean, to value. on mostly They similar a platform do QC acid have and just much the of Just to comes that a I to an

X, over have we the As find know, years, very in way you a CMV the Phase developed a where X variant. as all mRNA we same to vaccine its we on and complex product,

if not for what like. going to going COVID look to vaccine It’s think so, the be about easier. is multi-valent And you

multi-valent the can is characterization, trust them another want of not yet in years. lot the people They that you, know with CMV analytical big method for you over in prove we’ve you discussion before, to because Thank had what And regulators, regulators see that these who with GMP So to so a differentiation setting around have Moderna. done don’t Mike. that pipe. is again me,

it. Thank you, guys. Got

you. Thank

response is go Gena of Barclays. ahead. from Wang Please next Your

the one two, Thank also you for to questions. IP I have related my also question. taking

ask So, wanted differently. to

also new general contract? It Just XXXX in variant how And seems from is global contracted that Steve. protect Actually, was more less XXXX between question initially sites to data. many is long than on would the how strain. be booster you like manufacturing wondering, little This to expect. Stephane, regarding the for have? the sufficient second And I versus me a narrow differences surprised was it XXXX.XX should also

you do sufficient after then that you just just single out approach. regarding shot the the could there, that should multi-variant you think But still will explanation? like lay did be explanation be would So, what for plan, And be protection? going the the still the

— hand — Stephane then that I’ll I’ll the Gena. your IP take maybe and Thanks, question question. to first it on back

I couple would a things note. So, of

titers first booster, seeing of the order two-fold variant-specific And the higher you between the little mRNA-XXXX.XXX. level titers when substantially but is give than of them. difference bit that’s less are there X,XXX on is suggested — you you as are The you

point. this All looking would that at day XX. is time we’re I This this Now, happening note point is already at that early right. an

be with at effectively, prime we in It it XX. strain the first a in of day We is And South identified XXXX.XXX. this case, first looking will also Africa. are is dose the

it’s actually, that could two there’s And it at both obviously, one you so, ways good. is, is look it, look

strain of neutralizing way increased first variant amount. by it of ancestral in looking the compare against the very is, if strains XXX an level the I and looks levels to other Africa, saw in the the only South that the this strain titers level that strain, that’s really two was XXX the ancestral case. in last titers comparison, you that I’m day variants getting these that think between approximately we direct against identified can that same the XXX achieved immune And or concern it’s to rapidly we’ve and similar like to response still at between are XX the we that the even so this

or XX the this not the also we think booster has with that’s to that’s can particularly be But is waning immunity is as well dose Gena. immunity neutralizing [ph] Stephane? across that we authorized to continue couldn’t encouraging. to and starts to day in so excited strain I that advantage choose primarily and about incomplete if a two, XX, strategy. priming useful it response to that very vaccine last to that of wouldn’t generally our be an a I provide us of that patient booster at That highlighting dose it is a were event is can a concerned substantially this news, is increasing longer, you think higher mRNA-XXXX, suggest a There to mRNA-XXXX after either as and about — of multi-valent data at going And even that evidence good think Now, increase what early even immunity, populations at say provide you’re matching you because strategy. a between there some the had level titers micrograms, benefit, that, in antigen. the high-risk

Stephen. Thanks, Sure.

So, Gena, In manufacturers, and products. I on of raw contract all kind material, multi-year of these, contracts. look we would of the drug kind substance at have drug

additional drug to right get supplies is orders lot place, Board billion soon substance, actually, we now XXXX, scenario. this as we substance and we a forget, XXXX the of have supply capacity drug suppliers. go a As site to even away the is the doses the actually our where for to of it Moderna biggest And billion a X X send of in not to lot authorization a

you. Thank

Thank you.

Geoff ahead. Bank Please from next Your with America. response Meacham of is go

I Thanks on guys. Hi. two so for the Good just much morning, COVID. question. had

leverage protein thus The high versus efficacy. reconcile possible? first then permutations, what’s second some XXXX even main the COVID-XX vaccines Thank with spike have to the the the what potential annual tell theoretically for with do far that some is, make world and could of it the the parts steps versus it’s to your for to trying next-gen minimal if to of modifying just data variants? use breakthroughs difficult, you you is, effectiveness when when does virus now, real technology you as the this one regulatory respect I’m the or of today, of that add just And different question need think you. boosters

you, Those are both Thank Jeff. questions. good

first So, one. the maybe I’ll take

the real by of translating published very we’ve against that our largest to be groups the use reinforce COVID-XX. it saw and efficacy in clinical to that — well real is which the with into trial disease seems First, we world CDC amount the has world against been continues evidence efficacy like seen high

death, see of season now, let’s of say, cases everybody in from bad, it’s not we though, to months concern still these you vaccination a year We in that risk because acutely, not very important note, maybe than after What in right? only most does is of is, XX the public kind in, thousands, the but primary right I hundreds this it’s happening think That’s winters, months? but maybe all a we big and not campaigns. in into health see it of could on that until our months? are happen situation think in And have well, that. willing scale. this others And is thousands tens months of what reemergence of be nine this a situation look away as the take that worse like flu see are we is I substantially really wait like look what’s really and obviously a spikes very difficult vaccination, to — into we could a that going it’s from a perspective to does bad

probably cases the guide let breakthrough decisions. almost to real we’re to for setting that have so, really that from point, in to it’s too year chance and a not wait data after late. re-vaccination a to start vaccination world At And for going

highest maintain is this the near that term of I vaccinated for to at well and at decision already. correct immunity are so, think level, very in and of sort we conservative broadest the this think And level continue try the populations the to

the associated cost re-infect worse burden a them with future, devastating that viruses of re-infections not five substantial Now, the that high-risk in years so this pandemic. that the hopefully, unprecedented to in viruses when if phase we’re really past it that believe epidemic fact case probability this beyond of three, the those mortality, that’s fact, immunocompromised. still We evolution into variant believe in populations, years sort they don’t you and continually look context. with we’re same, current have We we than well we older going by there’s the or the epidemics do, would couple be and Day still that’s the phase in SARS-CoV-X the just and pandemic disease the to weeks healthcare of four, have endemic we think now, know from beyond hundreds where a take happened, created and respiratory be previous they re-infections SARS-Cov-X ago, we lesson is coronavirus almost that real Vaccines at shared whether of for particularly from but as and, be coronavirus see a that you years effect can in later, that, that

add and certainly to more it’s going or multi-valency for think so, valencies, believe be anybody don’t not, whether more continual the whether for. for that we need there is to And reason, and preparing I we’re it. can situation say a boosters, continues a But it’s annual

second And, on the Stephen… the or just on question different Stephane, modalities

that, different of the them, if And apologize. if vaccines it’s Yeah, efficacy seeing focus Geoff. modalities across now I immunogenicity. your to the in high pretty on I’m to antigens COVID-XX. protein That entry all is second sorry. possible looking you non-spike protection? the spike remiss definitely conclusive based the think question, you trying is on RNA messenger look provided right degree possible. spike you be vaccines, Phase think theoretically X on Yeah. that is the pretty after forward certainly we’re So, I past it what different But evidence from of Is think multiple large but being vaccines would the that I parts this the is and so possible, is antigens [ph] of expressed. going have clear trials protein look prevent of of could the same value provide I

re-demonstrate difficult be if a that choices terms where good probably, have we that may of you many you increasingly went down so route, So, think to you efficacy, that I world in would have vaccines. in

exactly we sure I’m And so, how go theoretically. path, not down that yeah, even

Thank you much. so Great. Okay.

Thank you.

go with response JPMorgan. next ahead. Your from Cory Please Kasimov is

on you think But you confidence to couple annual existing if anticipated to modeling based on negotiated have modeling price is should in do Good then people how really a you fill on of contracts a questions. Thank have a the that been going back doses the has to discussions being just ones future we booster this of to asked the that up have want for ways. billion there second for go purposes in be comparable XXXX could single basically topic future? And the kind taking see perspective, year, X currently for next know in I morning, much currently demand to to is be what to assuming supply points are question contracts. the pricing Hey. XXXX? from that taking getting I of are future you place, and Thanks are stable negotiations the the guys. if want especially for different you.

Yeah.

Corinne, stab So, miss Cory. just let color. add me take the at anything, some a question, And I if please

said forward. hearing So, looking mRNA my we’re from this I is in customer, the an becoming from as markets remarks, what

vaccinate And have year the math are so, then are you all mRNA doesn’t look there on across children future planet. adults, at if not you even then across going adolescence, players adults And what globe, the And And to boosting. The so and not then are the the needs many fear have to in this the get the world. you vaccinated work. you market.

up the oh, I add on best Understand, I what that the year Cory? don’t get country to between the and to the series thing. I anymore So, want I building saying, multiple, I ago. as some you a people thing this a be those vaccine for reason looking it governments — want based for want and I’m because want back and is third world vaccine get a is booster-specific, of cost. today. I when discussion ago, you we variant year supply is, year the to discussion being mRNA mix a my believe all need the prime on with pieces because we are with because the not second a This want cheap going its suppliers this The adenovirus daily at than the fourth billion multi-variant, we feet. X different was is boosters world. have a A engagements very set around It’s up is what

modeling question the on And pricing purpose? No. for Yeah.

Yeah.

will your discussion you there I but is On company cost at will give the This any but at is this company. The there discussion again, price more no pricing, small and color, all, a price is at gone. is $X.

you, Okay. perfect. Thank All right, Stephane.

Thank you.

Okay.

Your Oppenheimer Hartaj next Please is from with Singh ahead. response & Company. go

what question, prime route on I Would the variants. would with going the boost becoming and microgram the in XX it’s the all booster A XXX that future you have for Thanks think the question with forward, you. just whether stick margins we is Thank Great. for color. potentially David, possibly question. against o your like kind also? goods of kind microgram the initial or then color, you’ll you these see and vaccine Thank cost any just when sold variations adjusted start just of the could what kind operating like OpEx, looking could XXXX flush And of once [ph] you also? about your think on And look XXXX, of XXXX then out? quarterly

at the Thanks, and Hartaj. take for stab David hand the first a then other. I’ll one it to

the to XX that micrograms, slightly at achieve seem a levels we consistent But least of on series, XX of So, previously larger subjects. a at on and and measured immunogenicity number as dose. looked that primary X microgram number shared microgram Phase with shared data by obviously, is today a data were XXX good the subjects published we small quite our looking

to something could we So, we Right? we protection will certainly to not there, can get primary that different whether populations yet there going have have as will clear or between look it’s to we’re are correlates look in doses. that at we bridge data don’t which at doses and/or a those at So, have. we of But XX to series. upon how we use microgram depend started those whether to we’ll look pursue

you potential higher pediatric in than As evaluating people need a an been primary shared, you even example, younger XX ones. this micrograms can has perhaps imagine, populations, in as in older don’t we do you are as a dose series

target or for at is dose for primary possible. is top whether as lot that or of across at data. will which looking we not us evaluate will upon can applications. But looking. the of carefully in all a a we depend a adapt there’s a Certainly, look And of So, series micrograms booster we’re things as XX it ahead of to continue dose terms whether we not that series our forward,

David. thanks, - the on question Go No. then David. And Great. ahead,

Yeah.

the goods goods operating XXXX. kind it’s of cost and is, cost I to and giving early manufacturing we’re beyond, up would little for at said, of the we’ve yields in had goods that, What seeing if of initial here foreseen ramped pleased been We’ve XXXX So, and what our far, production cost been initially as have say start trends guess, expense we we’ve say I’d in of you guidance US. quite did thus as as look better I we that what I as the than is with planning. seen, a

planning reiterated think very helpful. assumption continues And XX% obviously goods. to now cost that’s today right we So right be the we of

As the and into therefore, manufactured be And margins gross you on in versus this are product, XXXX, Company. therapeutics, on. get very a levels, you of of will for — margins to it’s we depend we of then goods very the price I cost move question out think much think will early building beyond vaccines comment terms operating and expenses, competitive which

in I out We see and up do the while as year. build to portfolio to And expenses continue And that. stable were as trending we quarter, overall move $X.X the to through we that billion — now first we to our at quite do drive invest the we’ll operating investment appropriately continue mentioned, globally.

to XXXX and as move guidance and beyond. we’ll precise give say, to better that, would you more do I here So, we’ll continue we and closer

Thank you. Great.

Thank you.

response Please Your is with next Company. from Joseph & Stringer Needham go ahead.

morning. questions. Thanks our for Good Hi. taking

one on another capacity Just here. manufacturing

us ramp in some COVID what to give the we potential the wondering could manufacturing the — next-generation like you. was maybe qualitatively if to you a vaccine would second-gen for manufacturing move are vaccines, I XXXX? have seen modularity technology. terms of the ramp of sense with even in potentially look you of As relative What of in terms these Thank capacity given

Stephane. It’s Yes.

XXXX been capacity. has by with constrained [ph] ramp So, manufacturing

this you year, extraordinary in reason So, those an we is QX, million number only to the the look only supply which XXX at if building because we quote-unquote is capacity. are

and add team as to down much faster about ramp. of is, his And it way manufacturing ramps hard think slowing the the a and follow-on capacity, will to products are so, increase the to Juan because new working lines the be is today

anticipate as you I we will through backfoot. launches, launch, about CMV be on that, the as So, the RSV not we about think multi-variant booster think

commercial of XXXX to did at for as We XXXX, end several As we be budget pandemic. of supposed the you know, the we were road. our part plan didn’t that down years

the get are so, anticipate to we trust on we’re love XXXX. more red And — has planet. to able to more in year because, sell I team me, phone but to stay we would we just can’t the all hot pandemic planning the of the their to team is calls constraint. were And be be turning done able would products from Corinne supply her protect this point, around lover job not and we going by for, to would a remarkable and help but because people, to

we’re anticipate which it launch, for and too aggressive. So that I that some X make variants product sure billion not supply we maybe capacity that for new is the might volume constrained, will people why think

the remarks, pay my to of these. in companies said I are with the pipeline As still going

the vaccine. behind just is multi-valent this so, And

So out, a months. couple manufacturing years look we’re at building six you of if for not and

We’re team we market make we going supply every market sure capacity that and products, to happy her launch so can that to Corinne have that that as the really the single can wants. dose be

for Thanks taking the Great. question.

Thank you.

Thank you.

Please Foroohar Mani from go of ahead. is SVB response next Leerink. Your

taking the quick I’m question. for Thanks on guys. Hey, one, starting financials. One

clarity CapEx as forward little going increase rest bit setting as this on of you’ve year. modest CapEx little primarily around a we a versus the for lot one-time of there’s quarter clarity Should reduction. build-out? of going a of level of that a think we And Or given gave You expanding capacity clarity, that investments — should COGS think forward? for secondarily, around then the

we absolute other royalties, way vaccines, related again the so use pretty per right would COGS in not Or think linearly to forward, are etc., different attributes, about suggest differences the think dose. it? to that product about that Going unit, between that’s

Yeah.

that continue the comment. So Is to in own guidance for invest a below? XXXX and question will we’ve and CapEx this because capacity and want last ongoing to again, we’ll the CapEx, able or vertical over above appropriate you that now, expect you company But be CapEx. somewhat precisely we’ll yet early scope bit increased months. I it’s I going be for that expect trend you of to our really of we’re look We understand guidance for to our precision Company. if — year CapEx, an for wouldn’t occurred think of to have is range therefore, yet. it on and it’s our unfortunately based ongoing what can be give future? the integration, if clear and think in beyond as that of level into on — I state steady think I reasonable not or I this a forward size Is the development a side will couple the it’s

right In it’s product, amount I to cost be the when impacted that materials, think terms in COGS, talking you’re really not the micrograms about some of of way the But manufacturing of significant. the by level materials at about will think it that’s this of product.

the it’s right as can you assumption manufacture think steady now. a simplest cost of as I pretty assume, we’re seeing So,

Great. asked And of been some it’s the a quick know I various contracting. forms. follow-up on in

and quarter-ish behind disclosures on from your do your actually in in the nothing do of the we and is guys volume? these and next what Or about now, volume, manufacturing. now, based XXXX, US doses. XX% the see share do market you every How for You the XXXX position to positioned competitor incumbent XXXX year, X% ongoing for you have mRNA about game Right for is influences And have better two? manufacturing US suggest that other with new up year are for between on think how you somewhere contracting US OUS being results i.e., you talked a whole catch right a on you the about does contracting delivered, a manufacturing lot to contracting and delivered duopoly deliveries? be between and stronger doses countries versus

good a it’s Yes, question.

said, plan we plan executing always was we are as So, on. the the

had MediaDaily, to that part so, we countries And will very too early to from will US reported manage the we I not the already. — piece spoke when come US. and we the quarter we way to going to knew capacity the those APAs, forget the not, not it’s year be up We you of is should many set And in able anticipated know, delivery XX the online. mean, as vaccine be, countries very, we export soon, the as if is,

and And so, we building capacity is supply the are the we adding US the to that in are going also world.

government. think to of US and in a we’d we QX So, US I QX once anticipate QX and shipments, into two obligation we acceleration very the countries our as go even the big outside met more as

helpful. — guys you to a hesitant/end real in really the in of of factor There has of be could not supply, couple been least to more comment as are terms where what that’s US that That’s on you’re reports you seeing Great. the in world starting And opposed vaccine media currently, demand? at certainly, market globally. limiting a

In keep published coming I numbers by Correct. think, you and down, saying. daily the US of at it CDC shipments supply, as not the it have is and for, they increasing we since the been is look see because per the the country mid-April number companies, exactly going roughly from on of if the day the you vaccination in

oversupply demand-driven It’s there of really now. vaccine. now a so, an problem And is

elder are And we are still that rate in very said, have going vaccine. every So you parts up active see day way vaccination they country across we with is know, the as looking, as have high too some states we many of where of very you that the country, vaccination.

the anymore. vaccine demand true January, one place or has that to was heard have this before to issue have actual other in supply to That a shift were going think going you were federal true The you announced see. that to based I leading as to is it of yesterday they from products on US As stop vaccine and doesn’t anymore. the government not

the let and in back Great. [ph] Thanks. others. I’ll queue get

Thank you.

Thank you.

Simon Baker with Redburn. is next Your response from go Please ahead.

Thank you for taking my questions.

to you misses of around just capacity. waivers. Stephane, IP manufacturing rather Firstly, back as going the than IP point waivers limited the debate that said global talk about the

of you also to that To October. your that, post sought going sticking eight-month financials. over would in any question mentioned months that exercise in just there to then non-recurring give SG&A seven I on And unilaterally SG&A across supply. following to support XXXX? given with enforcement costs company think in primary quick about freedom you David, we think so that year. the T-cell vaccine, for QX wondered the if that could the any I Slide data vaccination do in a six- waive effectively the And knowledge, as to the announced, has the QX period you the response back much. IP were on of on just elements XX, to you us have in related to So, Thanks one-off operate? start-up back you color just some evolution

much. so Thank you

first on the the the financials. one think I and take So will David Stephen T-cell and IP

clinical to study. of So, after is what quickly. doesn’t the company happen aware out of I’m asking to make would how before have start mRNA. to that back not regulators described, one size that going to I And first mRNA GMP Again, figure the going any

the even this that We that think at monitoring really XXXX. we impact, is of have, I will T-cells? very but but field stage, XXXX Stephen closely course, on as the point are this always not impossible

today we the So from is on an initial have analysis the data boosters.

at are elements. as announced, with looking the We are looking running they NIH, and at other study series previously been ourselves a — the we’ve vaccination and we also study primary

six, in studies T-cell in responses we with data — we Phase future, X it T-cell the on and between across if this plan own the and so, out and much And point. boosters. that T-cell waning general historical important T-cells. of the in easier becomes studies titers with mid-term. specific But will at data encouraged previously Phase We and in our get We can do we T-cell correlation wider have perhaps not in by as to And NIH public measure X pretty have do a reported data over look have the immunity are do the range a this at time months But our at to subjects we ongoing any on point, neutralizing data those obviously well. that on our don’t David? T-cell yet are XX obviously

Yeah.

the we of up gave start level first would terms commercial, it but expenses second through you incurred quarter quarter, start commercial, we the around move of notably you one-time fourth the the expecting in thought guidance trend some the I sooner, set-up we last expect businesses in in in will yeah, expenses but year, if we start in that’s we’re see expenses, at would I now preponderance now we spend therefore, including which billion why as operating year, world, will quarter. that continue. total in forward of had the the to that the in first $X.X say, including So, some that to the And

we spend running of on global that quite is to size a business that So, reasonable, level honest. this basis, a be think

you All very right. much. Thank

further back no now I the showing to Stephane questions turn at over Bancel. this conference like I’m time. would to

much We safe, you Bye. at Thank seeing so May Stay Science in you questions. forward Day look a call today’s to day. on for the participating Have XX. everybody. nice for great and

concludes Thank you gentlemen, and conference call. that participation. Ladies your for today's

You all day. may have disconnect. a And wonderful you